Clinical trials · Washington, D.C., DC
Pulmonary Disease clinical trials in Washington, D.C.
We’re tracking 35 recruiting pulmonary disease studies with a site in or near Washington, D.C. — including Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Washington D.C., District of ColumbiaAges 18–80 - NCT07190222RecruitingPhase 3
New medicine for COPD with frequent flare-ups
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Washington D.C., District of ColumbiaAges 40–80 - NCT06283966RecruitingPhase 3
Triple inhaler for COPD with heart risk
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Washington D.C., District of ColumbiaAges 40–80 - NCT06526195Recruiting
A study of CardioMEMS and HeartMate 3 for advanced heart failure
This trial tests if a combination of a tiny lung-artery pressure sensor (CardioMEMS) and a mechanical heart pump (HeartMate 3) is safe and effective for people with advanced heart failure. If you qualify, you'll either get the heart pump plus standard medical therapy, or continue with standard therapy alone and have your pressure monitored remotely.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05153967Recruiting
Study late effects after sickle cell curative treatments
This study looks at long-term health effects after curative treatments for sickle cell disease, such as bone marrow transplant. Your participation helps researchers understand what changes over time after treatment, and what might need monitoring or care.
Washington D.C., District of ColumbiaAges 4–65 - NCT02803242Recruiting
Patient research network for people with lung symptoms
This trial enrolls adults to help build a patient-powered research network for chronic lung disease. If you join, you’ll likely be asked to complete surveys or provide information to help researchers learn how symptoms and health outcomes change over time.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05521789RecruitingPhase 4
Erector spinae block for thoracic surgery pain relief
This trial tests a specific pain-block injection (called an erector spinae block) to help with pain during thoracic surgery that removes part of the lung. You might benefit from better pain control and possibly fewer pain medicines, depending on what the study finds.
Washington D.C., District of ColumbiaAges 18–90 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Silver Spring, MarylandAges 40 years+ - NCT00001352Recruiting
Understanding Why Some People Get Fungal Infections
This study looks at genetic reasons why some people are susceptible to a serious fungal infection called cryptococcosis. Researchers will collect blood samples and perform genetic testing to understand the immune system differences that make certain individuals more vulnerable to this infection.
Bethesda, MarylandAges 18–99 - NCT00001532Recruiting
How Genes Affect Lung Disease Development
This research study examines how genetic factors contribute to various lung diseases, including alpha-1 antitrypsin deficiency, cystic fibrosis, and chronic obstructive pulmonary disease. Researchers want to understand why some people develop lung disease and how genetics plays a role, which may help improve treatment in the future.
Bethesda, MarylandAges 2–90 - NCT01730092Recruiting
Study of blood and imaging biomarkers in pulmonary artery hypertension
This study tracks natural changes in “biomarkers” (measurable signals in blood) and imaging findings in people with pulmonary arterial hypertension (PAH) or suspected PAH. It also includes healthy people for comparison, helping researchers understand what these signals mean over time.
Bethesda, MarylandAges 18–100 - NCT07613099RecruitingPhase 3
Testing a new PET scan to detect lung and heart scarring
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
Bethesda, MarylandAges 18–100 - NCT00077909Recruiting
Study of Lung Proteins in Patients With Pneumonia
This research study examines proteins in fluid collected from your lungs during a breathing tube procedure (bronchoscopy) to better understand pneumonia. By studying these proteins, researchers hope to improve how doctors diagnose and treat lung infections.
Bethesda, MarylandAges 3–99 - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Falls Church, VirginiaAges 40 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Falls Church, VirginiaAges 21 years+ - NCT06878261RecruitingPhase 3
Tezepelumab for moderate to very severe COPD
This study tests a new medication called tezepelumab (given as a shot) to see if it can reduce COPD flare-ups in people with moderate to very severe COPD who have had recent flare-ups despite using inhalers. It may be an option for those with higher levels of eosinophils (a type of white blood cell) in their blood.
Potomac, MarylandAges 40–80 - NCT06961214RecruitingPhase 3
Testing a new biologic for COPD with type 2 inflammation
This trial tests a medicine called depemokimab for people with COPD and a specific type of inflammation (type 2). It aims to see if it can reduce flare-ups when added to standard inhaler therapy.
Rockville, MarylandAges 40–80 - NCT07684820RecruitingPhase 2
A study of ExPD-101 for COPD with chronic bronchitis and frequent flare-ups
This study tests an experimental drug (ExPD-101) given daily as a pill for 52 weeks for people with COPD who have chronic bronchitis and frequent flare-ups. It compares the drug to a placebo (inactive pill) to see if it reduces flare-ups and improves symptoms.
Burke, VirginiaAges 40–85 - NCT06883305RecruitingPhase 3
Testing tezepelumab for moderate to severe COPD
This trial tests tezepelumab, an injected medication, for people with moderate to very severe COPD who still have flare-ups despite using standard inhalers. It may help reduce flare-ups and improve breathing for those with higher eosinophil levels.
Columbia, MarylandAges 40–80 - NCT06751537Recruiting
Testing a wearable device for COPD severity
This trial tests a wearable device (WearME) that tracks your breathing and activity to see how well it can measure COPD severity. It may help you and your doctor better understand your lung function at home.
Baltimore, MarylandAges 21–100 - NCT05297279Recruiting
Omega-3 diet program for people with COPD
This trial tests whether increasing omega-3 (from diet and/or supplements) helps people with COPD. It enrolls people with low omega-3 intake and asks them to follow a specific dietary plan during the study.
Baltimore, MarylandAges 40 years+ - NCT06376994RecruitingPhase 3
Clean air study for COPD
This study tests if using air cleaners at home improves lung health in people with COPD. If you qualify, you may get an air cleaner for your home and be followed for 12 months.
Baltimore, MarylandAges 40 years+
Hear when a new Pulmonary Disease trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Pulmonary Disease trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting pulmonary disease studies listed above.
- National Institutes of Health Clinical Center · 6 studies
- Johns Hopkins University · 4 studies
- Inova Fairfax Medical Campus · 3 studies
- Research Site · 3 studies
- Adventist Healthcare White Oak Medical Center · 2 studies
- Children's National Medical Center · 2 studies
- George Washington University Hospital · 2 studies
- Georgetown University Medical Center · 2 studies
What taking part in a pulmonary disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there pulmonary disease clinical trials near Washington, D.C.?
- Yes. We're currently tracking 35 recruiting pulmonary disease studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a pulmonary disease study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a pulmonary disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New pulmonary disease studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.